NRC director granted 22,625 options at $11.61; 2035 expiry
National Research Corp (NRC): Director stock option grant reported.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
National Research Corp (NRC): Director stock option grant reported. A Form 4 shows Donald M. Berwick, a director, was granted 22,625 stock options on 10/17/2025 under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.
The options have an exercise price of $11.61 per share, became exercisable on 10/17/2025, and expire on 10/17/2035. The derivative acquisition price was listed as $0. Ownership is reported as Direct (D).
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 22,625 | $0.00 | $0.00 |
Footnotes (1)
- F1. This award is a grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NRC (NRC) disclose in this Form 4?
How many options were granted and at what exercise price for NRC (NRC)?
When do the granted NRC (NRC) options become exercisable and when do they expire?
What plan governed the NRC (NRC) director’s option grant?
Why was the option grant made to the NRC (NRC) director?
What was the derivative security price listed in the NRC (NRC) Form 4?
How is ownership reported for this NRC (NRC) option grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.